Stay updated on Nivolumab for Stage IIB-IIC Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Stage IIB-IIC Melanoma Clinical Trial page.

Latest updates to the Nivolumab for Stage IIB-IIC Melanoma Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe page presents details for a completed Phase 2 nivolumab trial for resected stage IIB–IIC melanoma, including eligibility criteria, treatment plan, outcomes, and study locations. It also includes record dates, investigator and sponsor information, and links to the study protocol.SummaryDifference49%

- Check14 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0; the study record still displays a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedA banner announces an NIH-wide transition in terminology from “Artificial Intelligence” to “Super Intelligence.” The clinical trial page content remains a 403 error.SummaryDifference1%

- Check28 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer’s site revision label changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check56 days agoChange DetectedThe study page now shows a 403 Forbidden error, replacing the previous study details and related metadata with an access-denied message. As a result, the clinical trial record is no longer viewable on the page.SummaryDifference18%

Stay in the know with updates to Nivolumab for Stage IIB-IIC Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Stage IIB-IIC Melanoma Clinical Trial page.